Foundation Medicine to Acquire SAGA Diagnostics’ Cancer Monitoring Technology

April 23, 2026 - 04:30

In a significant move to enhance its capabilities in detecting residual disease, Foundation Medicine has announced its acquisition of SAGA Diagnostics' pioneering cancer monitoring technology. The deal centers on SAGA's minimal residual disease (MRD) platform, known as Pathlight, which is designed to identify exceedingly small traces of cancer that may remain after treatment.

This strategic acquisition positions Foundation Medicine to integrate highly sensitive, personalized monitoring tools into its existing comprehensive genomic profiling services. The Pathlight platform utilizes advanced sequencing to track unique, patient-specific mutations with a focus on solid tumors, offering the potential for earlier detection of recurrence than traditional methods. Experts suggest this technology could be crucial for guiding more timely and personalized treatment decisions, ultimately aiming to improve patient outcomes.

The integration of SAGA's MRD technology is expected to create a more complete continuum of cancer care, from initial diagnosis and therapy selection through to long-term surveillance. By adding this sensitive monitoring solution to its portfolio, Foundation Medicine strengthens its role in enabling clinicians to make more informed decisions across a patient's entire cancer journey. Financial terms of the agreement were not immediately disclosed. The completion of the acquisition is subject to customary closing conditions.